ImmuneOnco Biopharmaceuticals Announces FDA Clearance to Initiate Phase I Clinical Trial for IMM2510/AXN-2510 in the U.S

Reuters

07-30

ImmuneOnco Biopharmaceuticals Announces FDA Clearance to Initiate Phase I Clinical Trial for IMM2510/AXN-2510 in the U.S

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has announced the initiation of a Phase I clinical trial for IMM2510/AXN-2510 in the United States, following clearance from the U.S. Food and Drug Administration (FDA). IMM2510/AXN-2510 is a PD-L1 and VEGF bispecific antibody currently under development. The trial's commencement marks a significant milestone in the company's collaboration with Axion Bio, a wholly-owned subsidiary of Instil Bio, Inc. As part of this development, ImmuneOnco has received a milestone payment of US$10 million from Instil Bio. To date, total payments under their License and Collaboration Agreement have reached US$30 million. Results from this trial are expected to be presented in the future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief on July 30, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2555593046"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2555593046\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2555593046?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-30 19:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555593046","market":"fut","top_or_hot":-1,"title":"ImmuneOnco Biopharmaceuticals Announces FDA Clearance to Initiate Phase I Clinical Trial for IMM2510/AXN-2510 in the U.S","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ImmuneOnco Biopharmaceuticals Announces FDA Clearance to Initiate Phase I Clinical Trial for IMM2510/AXN-2510 in the U.S\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has announced the initiation of a Phase I clinical trial for IMM2510/AXN-2510 in the United States, following clearance from the U.S. Food and Drug Administration (FDA). IMM2510/AXN-2510 is a PD-L1 and VEGF bispecific antibody currently under development. The trial's commencement marks a significant milestone in the company's collaboration with Axion Bio, a wholly-owned subsidiary of <a href=\"https://laohu8.com/S/TIL\">Instil Bio, Inc.</a> As part of this development, ImmuneOnco has received a milestone payment of US$10 million from Instil Bio. To date, total payments under their License and Collaboration Agreement have reached US$30 million. Results from this trial are expected to be presented in the future.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief on July 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmuneOnco Biopharmaceuticals Announces FDA Clearance to Initiate Phase I Clinical Trial for IMM2510/AXN-2510 in the U.S</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmuneOnco Biopharmaceuticals Announces FDA Clearance to Initiate Phase I Clinical Trial for IMM2510/AXN-2510 in the U.S\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-30 19:37</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ImmuneOnco Biopharmaceuticals Announces FDA Clearance to Initiate Phase I Clinical Trial for IMM2510/AXN-2510 in the U.S\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has announced the initiation of a Phase I clinical trial for IMM2510/AXN-2510 in the United States, following clearance from the U.S. Food and Drug Administration (FDA). IMM2510/AXN-2510 is a PD-L1 and VEGF bispecific antibody currently under development. The trial's commencement marks a significant milestone in the company's collaboration with Axion Bio, a wholly-owned subsidiary of <a href=\"https://laohu8.com/S/TIL\">Instil Bio, Inc.</a> As part of this development, ImmuneOnco has received a milestone payment of US$10 million from Instil Bio. To date, total payments under their License and Collaboration Agreement have reached US$30 million. Results from this trial are expected to be presented in the future.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief on July 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01541","symbol_name":"宜明昂科-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nNDL3Gr3D0:1","article_id":"2555593046","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555593046","pubTimestamp":1753875436,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ImmuneOnco Biopharmaceuticals  Inc. has announced the initiation of a Phase I clinical trial for IMM2510/AXN-2510 in the United States, following clearance from the U.S. Food and Drug Administration . IMM2510/AXN-2510 is a PD-L1 and VEGF bispecific antibody currently under development. The trial's commencement marks a significant milestone in the company's collaboration with Axion Bio, a wholly-owned subsidiary of Instil Bio, Inc. As part of this development, ImmuneOnco has received a milestone payment of US$10 million from Instil Bio. To date, total payments under their License and Collaboration Agreement have reached US$30 million. Results from this trial are expected to be presented in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or le","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01541":"宜明昂科-B","TIL":"Instil Bio, Inc.","BK4505":"高瓴资本持仓","BK1161":"生物科技","BK4139":"生物科技"},"translate_title":"ImmuneOnco Biopharmaceuticals宣布FDA批准在美国启动IMM2510/AXN-2510的I期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01541":0.9,"TIL":0.9},"content_text":"ImmuneOnco Biopharmaceuticals Announces FDA Clearance to Initiate Phase I Clinical Trial for IMM2510/AXN-2510 in the U.S\n    \n\n        ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has announced the initiation of a Phase I clinical trial for IMM2510/AXN-2510 in the United States, following clearance from the U.S. Food and Drug Administration (FDA). IMM2510/AXN-2510 is a PD-L1 and VEGF bispecific antibody currently under development. The trial's commencement marks a significant milestone in the company's collaboration with Axion Bio, a wholly-owned subsidiary of Instil Bio, Inc. As part of this development, ImmuneOnco has received a milestone payment of US$10 million from Instil Bio. To date, total payments under their License and Collaboration Agreement have reached US$30 million. Results from this trial are expected to be presented in the future.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief on July 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}